解放军医药杂志Issue(9)：47-50,4.DOI:10.3969/j.issn.2095-140X.2014.09.013
多西他赛联合表柔比星新辅助化疗治疗炎性乳腺癌效果观察
Clinical Observation of Docetaxel Combined with Epirubicin on the Neoadjuvant Chemotherapy for Inflammato-ry Breast Cancer
陈金辉 1苗玲玲 1蒋志斌1
作者信息
- 1. 050082 石家庄，解放军白求恩国际和平医院普外二科
- 折叠
摘要
Abstract
Objective To observe the therapeutic efficacy,toxic reaction and prognosis of Docetaxel(DOC) combined with Epirubicin( EPI)on the neoadjuvant chemotherapy for inflammatory breast cancer( IBC). Methods A total of 53 IBC patients during July 2008 and October 2013 were divided into research group(n=22)and control group (n=31)based on different chemotherapies. The research group was treated with DOC combined with EPI,while the control group received 5-Fluorouracil(5-FU)combined with EPI and Cyclophosphamide(CTX),and one course was 21 d. Radical resection was performed 3-4weeks after a 4-course chemotherapy. Curative effect and toxic reaction were e-valuated after the operation in the two groups,and the prognosis was evaluated after one year of follow-up. Results Compared with those in control group,the values of partial remission and total effective rate were significantly higher in research group(P<0. 05). The radical resection was not performed because of developed pathogenetic condition for 1 patient in research group and 2 patients in control group. The one-year follow-up showed that the metastasis rate in re-search group was significantly lower than that in control group,while the disease free survival rate in research group was significantly higher than that in control group(P<0. 05). Conclusion Chemotherapy plan of Docetaxel combined with Epirubicin has better efficacy in the treatment of IBC,and the relevant toxic and side-effect are tolerable,thus it may be an preferred neoadjuvant chemotherapy plan for IBC.关键词
炎性乳腺肿瘤/新辅助化疗/多西他赛/表柔比星/药物毒性Key words
Inflammatory breast neoplasms/Neoadjuvant chemotherapy/Docetaxel/Epirubicin/Drug toxicity分类
医药卫生引用本文复制引用
陈金辉,苗玲玲,蒋志斌..多西他赛联合表柔比星新辅助化疗治疗炎性乳腺癌效果观察[J].解放军医药杂志,2014,(9):47-50,4.
